US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Argen X NV

562.00

0.0000

Volume:- -

Turnover:- -

Market Cap:33.61B

PE:-162.09

High:562.00

Open:562.00

Low:562.00

Close:562.00

Loading ...

Overview Company News Filings

Is argenx SE (ARGX) the Most Profitable Growth Stock to Buy Now?

Exploring High Growth Tech Stocks In Europe

Simply Wall St.

argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Is Argenx SE (ARGX) the Best Growth Stock to Buy According to Billionaires?

FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting

argenx Announces Annual General Meeting of Shareholders on May 27, 2025

Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients

Is Argenx SE (ARGX) The Most Profitable Biotech Stock To Buy Right Now?

Artisan Small Cap Fund Sold argenx SE (ARGX) as it Exceeded Small-Cap Mandate

Exploring 3 High Growth Tech Stocks in Europe

Simply Wall St.

argenx to Present at TD Cowen 45th Annual Healthcare Conference

Here’s Why argenx SE (ARGX) Rose in Q4

Q4 2024 Halozyme Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

Exploring High Growth Tech Stocks With Promising Potential

Simply Wall St.

Is argenx SE (ARGX) the High Growth International Stock to Invest in Now?

Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?

Earnings Estimates Rising for Argenx (ARGX): Will It Gain?

Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ARGNF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARGNF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARGNF\",,,,,undefined,":{"symbol":"ARGNF","market":"US","secType":"STK","nameCN":"Argen X NV","latestPrice":562,"timestamp":1749240000000,"preClose":562,"halted":0,"volume":0,"delay":15,"floatShares":59396720,"shares":59796273,"eps":-3.467175,"marketStatus":"Market Closed","change":0,"latestTime":"06-06 16:00:00 EDT Delay","open":562,"high":562,"low":562,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-3.467175,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":562,"volumeRatio":0.2840922004190928},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARGNF\",,,,,undefined,":{"symbol":"ARGNF","floatShares":59396720,"roa":"-0.21%","roe":"17.36%","lyrEps":-5.161043,"volumeRatio":0.2840922004190928,"shares":59796273,"dividePrice":0,"high":562,"amplitude":0,"preClose":562,"low":562,"week52Low":373.5,"pbRate":"6.11","psRate":"12.71","week52High":697.42,"institutionHeld":0,"latestPrice":562,"eps":-3.467175,"divideRate":0,"volume":0,"delay":15,"ttmEps":-3.467175,"open":562,"prevYearClose":652.35,"prevWeekClose":562,"prevMonthClose":562,"prevQuarterClose":697.42,"fiveDayClose":562,"twentyDayClose":697.42,"sixtyDayClose":697.42},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARGNF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532191023","title":"Is argenx SE (ARGX) the Most Profitable Growth Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2532191023","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532191023?lang=en_us&edition=fundamental","pubTime":"2025-05-01 15:33","pubTimestamp":1746084826,"startTime":"0","endTime":"0","summary":"We recently published a list of 13 Most Profitable Growth Stocks to Buy Now. In this article, we are going to take a look at where argenx SE  stands against other most profitable growth stocks to buy now.READ ALSO:10 Most Profitable Blue Chip Stocks to Buy Now. Business surveys have also been quite grim – Hamilton Lane recently reported that at least 62% of CEOs see a recession on the horizon, while the 6-month Capex expectations fell to the lowest level since the pandemic. It is now clear that pretty much everyone is thinking about a recession now, and that’s ac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-se-argx-most-profitable-073346468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU0889565916.HKD",".IXIC","NQmain","TSYW.SI","ARGX","TQQQ","MNQmain","USJW.SI","PSQ","ARGNF","USAW.SI","SQQQ","LU0109394709.USD","LU0320765992.SGD","BK4585","BK4505","NVIW.SI","QID","QLD","BK4588"],"gpt_icon":1},{"id":"2532904297","title":"Exploring High Growth Tech Stocks In Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2532904297","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532904297?lang=en_us&edition=fundamental","pubTime":"2025-05-01 13:40","pubTimestamp":1746078009,"startTime":"0","endTime":"0","summary":"As European markets experience a notable upswing, with the STOXX Europe 600 Index rising by 2.77% amid easing trade tensions and positive economic signals, investors are increasingly focusing on high-growth tech stocks that show resilience and potential in such dynamic conditions. In this environment, a good stock is often characterized by its ability to adapt to market changes and leverage technological advancements to drive growth, making it a key consideration for those exploring opportunities in Europe's burgeoning tech sector.Click here to see the full list of 221 stocks from our European High Growth Tech and AI Stocks screener.Remedy Entertainment Oyj, amidst a challenging landscape for tech firms, has demonstrated resilience with an 18.9% annual revenue growth, outpacing the Finn","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-054009674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","CD","ARGX","BK4505","BK4139","BK4116","OTGLY","BK4585","BK4588","RMDEF","ARGNF","OTGLF"],"gpt_icon":0},{"id":"2532104431","title":"argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532104431","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532104431?lang=en_us&edition=fundamental","pubTime":"2025-05-01 13:00","pubTimestamp":1746075600,"startTime":"0","endTime":"0","summary":"May 1, 2025Amsterdam, the Netherlands – argenx , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET  to discuss its first quarter 2025 financial results and provide a business update.Belgium 32 800 50 201France  33 800 943355Netherlands 31 20 795 1090United Kingdom 44 800 358 0970United States 1 888 415 4250Japan  81 3 4578 9081Switzerland 41 43 210 11 32. Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-report-first-quarter-2025-050000914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU0889565916.HKD","ARGX","LU0109394709.USD","ARGNF","BK4585","BK4139","BK4505","LU0320765992.SGD"],"gpt_icon":0},{"id":"2530700414","title":"argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2530700414","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530700414?lang=en_us&edition=fundamental","pubTime":"2025-04-28 13:00","pubTimestamp":1745816400,"startTime":"0","endTime":"0","summary":"VYVGART is first-and-only targeted IgG Fc-antibody fragment for CIDP. First novel mechanism of action for CIDP treatment in more than 30 years. CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial. European Commission  decision on marketing authorization application expected within approximately two months. “Our mission is to develop innovative, targeted treatments for patients with rare and severe autoimmune diseases, who continue to face significant unmet needs. The positive CHMP opinion for VYVGART in CIDP brings us one step closer to providing patients across Europe with a transformational new treatment option that provides meaningful functional improvement,” said Luc Truyen M.D., Ph.D., Chief Medical Officer, argenx. “VYVGART is the first and only targeted IgG Fc-antibody fragment for CIDP and if approved, would mark the first treatment in Europe with a novel, precision mechanism of action for CIDP patients in 30 years.”\"For the patient population repre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-announces-positive-chmp-opinion-050000869.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4215","ARGX","BK4588","BK4585","EC","MAA","BK4201","BK4087","ARGNF","BK4139","CHMP"],"gpt_icon":0},{"id":"2527211278","title":"Is Argenx SE (ARGX) the Best Growth Stock to Buy According to Billionaires?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527211278","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527211278?lang=en_us&edition=fundamental","pubTime":"2025-04-15 02:03","pubTimestamp":1744653796,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Argenx SE  stands against other best growth stocks to buy according to billionaires.Can the Stock Market Have a Big Rebound?While addressing the concerns that if the market is in a bear market, Lee noted that if we define a bear market by stocks grinding and losing money, then this has been happening since December 2024. However, if you define a bear market as unleashing a type of financial tightening that leads to a recession, the current market does not fit that criteria. Lee acknowledged that it does feel like a bear market for an average person.Why are we interested in the stocks that hedge funds pile into?The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-se-argx-best-growth-180316048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","BK4588","QLD","LU0320765992.SGD","USAW.SI","MNQmain",".IXIC","NVIW.SI","LU0109394709.USD","PSQ","ARGX","LU0889565916.HKD","NQmain","BK4505","QID","ARGNF","USJW.SI","SQQQ","BK4585","BK4139","TQQQ"],"gpt_icon":1},{"id":"2526647240","title":"FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting","url":"https://stock-news.laohu8.com/highlight/detail?id=2526647240","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526647240?lang=en_us&edition=fundamental","pubTime":"2025-04-12 05:41","pubTimestamp":1744407712,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration  on Thursday approved a new option for patients to self-inject Argenx SE’s  Vyvgart Hytrulo with a prefilled syringe  for adult patients with generalized myasthenia gravis  who are anti-acetylcholine receptor  antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy .Vyvgart Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional.The single-dose prefilled subcutaneous injection was developed as part of argenx’s exclusive partnership with Halozyme Therapeutics Inc’s  Enhanze drug delivery technology, enabling rapid, high-volume biologics delivery.Also Read: Argenx’s Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients. The approval of the Vyvgart Hytrulo prefilled syringe for self-injection is supported by data from studies evaluating its bioequivalenceto Vyvgart Hytr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-argenxs-vyvgart-hytrulo-214152717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","IE00BZ1G4Q59.USD","LU0320765646.SGD","LU2028103732.USD","LU2357305700.SGD","LU2111349929.HKD","BK4534","LU1720051108.HKD","LU1074936037.SGD","LU1989772923.USD","LU0098860793.USD","HALO","LU0106261372.USD","LU1162221912.USD","LU2023251221.USD","LU1363072403.SGD","LU2347655156.SGD","LU0320765992.SGD","BK4139","LU0971096721.USD","BK4505","LU0795875086.SGD","LU1732800096.USD","LU0225283273.USD","LU0053671581.USD","LU1732799900.SGD","BK4588","LU0158827948.USD","LU1989772840.SGD","LU2089283258.USD","LU2133065610.SGD","BK4516","ARGX","BK4127","LU2089284900.SGD","BK4581","ARGNF","LU0889565916.HKD","IE00BKVL7J92.USD","LU0158827781.USD","LU0109394709.USD","LU1548497426.USD","LU1720051017.SGD","LU0314104364.USD","BK4504","LU1668664300.SGD","LU0795875169.SGD","LU0267386448.USD","LU0912757837.SGD","HOME","LU0106831901.USD"],"gpt_icon":0},{"id":"2526646880","title":"argenx Announces Annual General Meeting of Shareholders on May 27, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2526646880","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526646880?lang=en_us&edition=fundamental","pubTime":"2025-04-12 04:01","pubTimestamp":1744401660,"startTime":"0","endTime":"0","summary":"AgendaIn addition to recurrent items on the agenda, such as the discussion and adoption of the 2024 annual accounts, an advisory vote on the company’s 2024 remuneration report, the discharge of the directors for their duties performed in 2024 and the authorization of the Board of Directors to issue shares and to limit or exclude pre-emptive rights in relation thereto, it is proposed to re-appoint Anthony Rosenberg as a non-executive director to the Board of Directors and to adopt a new remuneration policy.The full agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage shareholders to use the voting by  proxy option as referred to in the convocation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-announces-annual-general-meeting-200100570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ARGX","ARGNF","BK4156"],"gpt_icon":0},{"id":"2526419788","title":"Argenx's Flagship Drug Vyvgart Shows Sustained Disease Control In Rare Neuromuscular Disease Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2526419788","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526419788?lang=en_us&edition=fundamental","pubTime":"2025-04-09 02:17","pubTimestamp":1744136274,"startTime":"0","endTime":"0","summary":"Argenx SE  showcased long-term data of Vyvgart  demonstrating sustained disease control of generalized myasthenia gravis  and chronic inflammatory demyelinating polyneuropathy  with a favorable safety profile.ADAPT-NXT Part B data demonstrated clinically meaningful improvements as early as Week 1 with Vyvgart’s bi-weekly and every three-week dosing schedules.Over the course of the study , 75% of patients showed sustained efficacy, achieving 2 points or more of improvement in MG activities of daily living  during more than 75% of study visits.In addition, more than half  of participants achieved minimal symptom expression  during the study.Also Read: Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval. Interim results of ADAPT-SC+ demonstrate consistent and repeatable improvements in MG-ADL  and MG Quality of Life  scores in gMG patients treated with Vyvgart Hytrulo.In addition, the majority of ADHERE patients who relapsed during ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenxs-flagship-drug-vyvgart-shows-181754819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARGX","LU0320765992.SGD","ARGNF","BK4139","LU0109394709.USD","BK4505","BK4585","LU0889565916.HKD","BK4588"],"gpt_icon":0},{"id":"2524494535","title":"Is Argenx SE (ARGX) The Most Profitable Biotech Stock To Buy Right Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2524494535","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524494535?lang=en_us&edition=fundamental","pubTime":"2025-04-02 21:47","pubTimestamp":1743601671,"startTime":"0","endTime":"0","summary":"We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Argenx SE  stands against other most profitable biotech stocks to buy right now.With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction. The sector has bounced back from a difficult 2024 and is set to grow significantly, thanks to developments in AI-driven drug discovery, personalized medicine, and the rising demand for biologics. The global biotech market was expected to grow by a robust 13%, from $483.0 billion in 2024 to $546.0 billion in 2025, according to MarketsandMarkets. The sector’s resilience and growth potential are demonstrated by this expansion.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-se-argx-most-profitable-134751572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765992.SGD","BK4139","BK4585","SQQQ","BK4505","LU0109394709.USD","LU0889565916.HKD","MNQmain","NQmain",".IXIC","TQQQ","USJW.SI","PSQ","ARGNF","QID","TSYW.SI","USAW.SI","ARGX","BK4588","NVIW.SI","QLD"],"gpt_icon":1},{"id":"2518743448","title":"Artisan Small Cap Fund Sold argenx SE (ARGX) as it Exceeded Small-Cap Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=2518743448","media":"Insider Monkey","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518743448?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:17","pubTimestamp":1741695454,"startTime":"0","endTime":"0","summary":"Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. US stocks concluded a strong year with strong gains in Q4. In Q4, the portfolio's performance was flat and narrowly trailed the Russell 2000 Growth Index. In 2024, the portfolio produced a robust absolute return that was in line with the Russell 2000 Growth Index but outperformed the Russell 2000 Index. In the quarter, its Investor Class fund ARTSX returned 0.61%, Advisor Class fund APDSX posted a return of 0.66%, and Institutional Class fund APHSX returned 0.67%, compared to a return of 1.70% for the Russell 2000 Growth Index. In addition, you can check the fund’s top 5 holdings to find out its best picks for 2024.Artisan Small Cap Fund stated the following regarding Argenx SE  in its Q4 2024 investor letter:. Inanother article, we discussed Argenx SE  and shared Baron Health Care Fund's views on the company. In add","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/artisan-small-cap-fund-sold-121734018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","NQmain","BK4588","LU0889565916.HKD","MNQmain","LU0109394709.USD","NVIW.SI","SQQQ","TQQQ","PSQ","BK4585","LU0320765992.SGD","USJW.SI","ARGX","BK4505","QID",".IXIC","USAW.SI","ARGNF","TSYW.SI","BK4139"],"gpt_icon":1},{"id":"2514391196","title":"Exploring 3 High Growth Tech Stocks in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2514391196","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514391196?lang=en_us&edition=fundamental","pubTime":"2025-02-28 13:08","pubTimestamp":1740719299,"startTime":"0","endTime":"0","summary":"Amid cautious optimism in Europe, the pan-European STOXX Europe 600 Index recently edged higher by 0.26% as investors weighed developments in U.S. trade policy and efforts to resolve the Russia-Ukraine conflict, while eurozone business activity showed signs of stagnation despite remaining in expansionary territory. In such a dynamic market environment, identifying high-growth tech stocks often involves looking for companies that demonstrate strong innovation capabilities and resilience to economic shifts, which are crucial factors given the current geopolitical and economic landscape.Click here to see the full list of 246 stocks from our European High Growth Tech and AI Stocks screener.Overview: Izertis, S.A. is a technological consultancy firm operating in Spain, Portugal, and Mexico with a market capitalization of 255.69 million.Operations: The company, alongside its subsidiaries, generates revenue primarily from providing technological consultancy services in Spain, Portugal, and Me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-3-high-growth-tech-050819940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4134","LU0889565916.HKD","LU2517655291.USD","BK4585","LU2517655028.SGD","LU0154245673.USD","LU0320765992.SGD","BK4139","LU1814569148.SGD","LU2362541273.HKD","ARGNF","LU0107464264.USD","BK4588","LU2362541513.USD","LU0109394709.USD","LU2517655374.HKD","BK4505","LU2362540622.SGD","ARGX","LU0154245756.USD","IT","PRS"],"gpt_icon":0},{"id":"2514032011","title":"argenx to Present at TD Cowen 45th Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2514032011","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514032011?lang=en_us&edition=fundamental","pubTime":"2025-02-25 14:00","pubTimestamp":1740463200,"startTime":"0","endTime":"0","summary":"February 25, 2025Amsterdam, the Netherlands – argenx , a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025 at 11:50 a.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-present-td-cowen-45th-060000504.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARGNF","BK4139","BK4207","BK4505","LU0320765992.SGD","TD","BK4585","BK4588","BK4566","LU0109394709.USD","ARGX","BK4137","LU0889565916.HKD","BK4127","HCSG","COWN","BK4156"],"gpt_icon":0},{"id":"2512817574","title":"Here’s Why argenx SE (ARGX) Rose in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2512817574","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512817574?lang=en_us&edition=fundamental","pubTime":"2025-02-19 23:58","pubTimestamp":1739980718,"startTime":"0","endTime":"0","summary":"Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The Fund performed roughly in line with the Benchmark, during a challenging quarter for the larger health care industry. A copy of the letter can be downloaded here. The fund declined 9.58%  in the quarter compared to a 9.75% decline for the Russell 3000 Health Care Index  and a 2.63% gain for the Russell 3000 Index . For the full year 2024, the fund appreciated 1.55% compared to 3.48% and 23.81% gains for the indexes. In addition, please check the fund’s top five holdings to know its best picks in 2024.In its fourth quarter 2024 investor letter, Baron Health Care Fund emphasized stocks such as Argenx SE . Argenx SE  is a biotechnology company focuses on developing therapies for the treatment of autoimmune diseases. The one-month return of Argenx SE  was -0.13%, and its shares gained 59.77% of their value over the last 52 weeks. On February 18, 2025, Argenx SE  stoc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-argenx-se-argx-rose-155838419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TQQQ","MNQmain","USJW.SI","BK4139","BK4505","NVIW.SI","LU0109394709.USD","QID","BK4585","USAW.SI","NQmain",".IXIC","BK4588","ARGX","ARGNF","SQQQ","TSYW.SI","QLD","LU0889565916.HKD","PSQ","LU0320765992.SGD"],"gpt_icon":1},{"id":"2512010612","title":"Q4 2024 Halozyme Therapeutics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2512010612","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512010612?lang=en_us&edition=fundamental","pubTime":"2025-02-19 20:10","pubTimestamp":1739967002,"startTime":"0","endTime":"0","summary":"Tram Bui; Vice President - Investor Relations and Corporate Communications; Halozyme Therapeutics Inc. Helen Torley; President, Chief Executive Officer, Director; Halozyme Therapeutics Inc. Nicole Labrosse; Chief Financial Officer, Senior Vice President; Halozyme Therapeutics Inc. Thank you, Tram, and good afternoon, everyone. Our strong fourth quarter results concluded what proved to be an exceptional year for Halozyme. I will start by recapping our record-breaking performance in 2024. Total revenue exceeded $1 billion for the first time, growing 22% over prior year. We also raised our financial guidance twice during the year, and I'm pleased to report that full year results exceeded our raised guidance for royalty revenue, adjusted EBITDA and non-GAAP EPS.We estimate that one million patients have now received drugs delivered subcutaneously with ENHANZE, establishing unsurpassed and we believe unsurpassable safety database to inform regulators and new partners. Importantly, multiple ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-halozyme-therapeutics-inc-121002596.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARGX","JNJ","HALO","ARGNF"],"gpt_icon":0},{"id":"2507521678","title":"Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2507521678","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507521678?lang=en_us&edition=fundamental","pubTime":"2025-01-30 22:40","pubTimestamp":1738248008,"startTime":"0","endTime":"0","summary":"Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. argenex SE  is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.argenex SE is a member of the Medical sector. This group includes 1010 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.Biodexa Pharmaceuticals PLC Unsponsored ADR  is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 4.9%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-argx-outperforming-other-medical-144008080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARGNF","ARGX"],"gpt_icon":0},{"id":"2507618617","title":"Exploring High Growth Tech Stocks With Promising Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2507618617","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507618617?lang=en_us&edition=fundamental","pubTime":"2025-01-30 13:02","pubTimestamp":1738213379,"startTime":"0","endTime":"0","summary":"As global markets experience a surge, with U.S. stocks reaching new heights amid optimism over trade policies and AI advancements, growth stocks have notably outperformed their value counterparts, highlighting investor enthusiasm for innovation-driven sectors. In this dynamic environment, identifying high-growth tech stocks involves evaluating companies that can leverage technological advancements and strategic partnerships to capitalize on emerging market opportunities.Click here to see the full list of 1231 stocks from our High Growth Tech and AI Stocks screener.Argenx's recent approval of VYVDURA in Japan for CIDP, a rare neuromuscular disorder, underscores its strategic focus on addressing unmet medical needs through innovative treatments. This follows their positive earnings report for Q3 2024, where revenue surged to $588.88 million from $339.84 million year-over-year and net income flipped to $91.41 million from a previous loss of $72.64 million. These developments highlight Arg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-050259657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ARGX","ARGNF"],"gpt_icon":0},{"id":"2505809052","title":"Is argenx SE (ARGX) the High Growth International Stock to Invest in Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2505809052","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505809052?lang=en_us&edition=fundamental","pubTime":"2025-01-23 15:19","pubTimestamp":1737616768,"startTime":"0","endTime":"0","summary":"We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a look at where argenx SE  stands against other high growth international stocks to invest in now.What To Expect From The Stock Market in 2025?On January 15, Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company shared his outlook for 2025. He believes that the market has lost some of its momentum as the prospects of more rate cuts in 2025 have gone slimmer. One of the reasons for less likely rate cuts came a few weeks ago with a stronger-than-expected job market report, which sparked a market dip. Moreover, on the same day, long-term interest rates went higher. The 10-year treasury yield climbed closer to the 5% mark which has haunted stocks in the past.While talking about large-cap stock performance, Timmer raises the question of whether this trend of narrow leadership will persist. He suggested that trends continue to move in the sa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-se-argx-high-growth-071928823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TSYW.SI","MNQmain","QLD","SQQQ","BK4139","ARGNF","NQmain","BK4585",".IXIC","BK4505","LU0109394709.USD","USAW.SI","USJW.SI","QID","BK4588","LU0889565916.HKD","ARGX","NVIW.SI","LU0320765992.SGD","PSQ","TQQQ"],"gpt_icon":1},{"id":"2505528050","title":"Is Ascendis Pharma (ASND) the High Growth International Stock to Invest in Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2505528050","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505528050?lang=en_us&edition=fundamental","pubTime":"2025-01-23 15:17","pubTimestamp":1737616652,"startTime":"0","endTime":"0","summary":"We recently published a list of 12 High Growth International Stocks to Invest in Now. In this article, we are going to take a look at where Ascendis Pharma A/S  stands against other high growth international stocks to invest in now.What To Expect From The Stock Market in 2025?On January 15, Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company shared his outlook for 2025. He believes that the market has lost some of its momentum as the prospects of more rate cuts in 2025 have gone slimmer. One of the reasons for less likely rate cuts came a few weeks ago with a stronger-than-expected job market report, which sparked a market dip. Moreover, on the same day, long-term interest rates went higher. The 10-year treasury yield climbed closer to the 5% mark which has haunted stocks in the past.While talking about large-cap stock performance, Timmer raises the question of whether this trend of narrow leadership will persist. He suggested that trends continue to move","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ascendis-pharma-asnd-high-growth-071732989.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","ASND","IE0031619046.USD","NQmain","IE00B66KJ199.SGD","IE00B7SZL793.SGD","MNQmain","USJW.SI","TQQQ","LU0889565916.HKD","IE00B19Z4B17.USD","BK4585","BK4505","USAW.SI","TSYW.SI","QLD","LU0320765992.SGD","NVIW.SI","MG","SQQQ","PSQ","LU0109394709.USD","BK4123","BK4139","QID","ARGX","BK4588","ARGNF"],"gpt_icon":1},{"id":"2504115648","title":"Earnings Estimates Rising for Argenx (ARGX): Will It Gain?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504115648","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504115648?lang=en_us&edition=fundamental","pubTime":"2025-01-18 01:20","pubTimestamp":1737134404,"startTime":"0","endTime":"0","summary":"Argenex SE  appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been a strong performer lately, and the momentum might continue with analysts still raising their earnings estimates for the company.Analysts' growing optimism on the earnings prospects of this company is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- has this insight at its core.The five-grade Zacks Rank system, which ranges from a Zacks Rank #1  to a Zacks Rank #5 , has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.For Argenx, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates cons","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/earnings-estimates-rising-argenx-argx-172004132.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARGNF","ARGX"],"gpt_icon":0},{"id":"2494316079","title":"Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2494316079","media":"TipRanks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494316079?lang=en_us&edition=fundamental","pubTime":"2024-12-28 19:28","pubTimestamp":1735385318,"startTime":"0","endTime":"0","summary":"Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. Argenx SE announced that Japan’s Ministry of Health, Labour and Welfare has approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy . This approval marks the first time the neonatal Fc receptor blocker has been authorized for CIDP treatment, providing patients with a convenient at-home self-injection option. The approval is based on the results of the ADHERE trial, which demonstrated significant clinical improvements in mobility, function, and reduction in relapse risk for patients treated with VYVDURA. This development strengthens Argenx’s position in the immunology market and expands treatment options for CIDP patients, while potentially impacting stakeholders by broadening access to innovative therapies.Argenx SE is a global immunology company dedicated to i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/argenx-secures-japanese-approval-vyvdura-112838412.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argenx-secures-japanese-approval-vyvdura-112838412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Argenx Secures Japanese Approval for VYVDURA in CIDP Treatment","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARGX","ARGNF","BK4588","LU0320765992.SGD","BK4139","BK4585","BK4505","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARGNF\",params:#limit:5,,,undefined,":[{"date":"2024-05-09","symbol":"ARGNF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715241600000,"name":null,"time":"Pre-Market","dateTimestamp":1715227200000,"actualEps":null},{"market":"US","date":"2022-10-27","symbol":"ARGNF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1666843200000,"reportTimeType":"pre","actualEps":null},{"date":"2022-05-12","symbol":"ARGNF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1652342400000,"name":null,"time":"","dateTimestamp":1652328000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARGNF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARGNF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3,"buy":0.65,"hold":0.05,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.65,"analysts":20,"updateTime":1744689600000}}}